Publication
Article
Pharmacy Times
Author(s):
Omnipod 5 Automated Insulin Delivery System
From: Insulet Corporation
The FDA has cleared an expanded indication for the Omnipod 5 automated insulin delivery system for use in adults with type 2 diabetes. The system was previously indicated for managing type 1 diabetes in patients 2 years and older, but it can now be used for both type 1 and type 2 diabetes. The software automatically adjusts insulin delivery by connecting to an alternate controller-enabled pump and integrated continuous glucose monitor, helping to simplify diabetes management for patients.
For more information: omnipod.com
Sparsentan (Filspari)
From: Travere Therapeutics, Inc
The FDA has announced full approval for sparsentan, an oral, oncedaily, nonimmunosuppressive treatment to significantly slow the decline of kidney function in adults with primary immunoglobulin A nephropathy. The approval is based on long-term confirmatory results from the PROTECT study, which demonstrated that the drug significantly slowed kidney function decline over a 2-year period compared with irbesartan. Researchers found a statistically significant treatment effect of 1.2 mL/min/1.73 m2 per year. The treatment was previously granted an accelerated approval in February 2023 based on preliminary, preclinical results from PROTECT.
For more information: filsparihcp.com
GLP-1 Support System
From: SoWell
SoWell has launched a 3-part supplement system SoWell Electrolytes, SoWell Protein, and SoWell Fiber that is designed to aid adverse effects caused by glucagon-like peptide-1 (GLP-1) medications. The products combine 17 ingredients that ease nausea, constipation, diarrhea, fatigue, headaches, muscle loss, weakened skin elasticity, and hair loss in patients who take GLP-1 medications. SoWell Electrolytes provide individuals with healthy hydration levels and includes vitamin B6 and trace minerals; SoWell Protein combines 25 g whey isolate, collagen protein, and digestive enzymes to maintain muscle mass and skin elasticity; and SoWell Fiber includes a combination of psyllium husk, guar gum, and apple pectin fiber to balance digestion.
For more information: getsowell.com
Betamethasone Valerate Foam, 0.12%
Compare with: Luxiq Foam
From: Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited has introduced betamethasone valerate foam, 0.12%. The foam is a medium-potency topical corticosteroid designed to relieve inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp. Betamethasone decreases the inflammation, itching, and redness that characterize dermatoses. Patients should be advised to massage the foam gently into the affected area until it is absorbed, and they should not cover the area with bandages or other dressings unless otherwise instructed by their physician. The foam will be available in 50-g and 100-g bottles.
For more information: alembicpharmaceuticals.com